Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jashodeep Datta

Showing results (91-100 of 140) with videos related to

Pageof 14
Sort By:
Elife|September 15, 2022
Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical studyIago de Castro Silva, Anna Bianchi, Nilesh U Deshpande, et al.
Molecular Cancer Therapeutics|September 14, 2021
Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic CancerAustin R Dosch, Samara Singh, Xizi Dai, et al.
Journal of Surgical Oncology|October 30, 2020
Surgical management of hepatocellular carcinoma patients with portal vein thrombosis: The United States Safety Net and Academic Center Collaborative AnalysisEmily L Ryon, Joshua P Kronenfeld, Rachel M Lee, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|June 18, 2022
Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United StatesTejeshwar Jain, Prateek Sharma, Bhuwan Giri, et al.
Journal of Surgical Oncology|April 19, 2023
Accuracy of models to prognosticate survival after surgery for pancreatic cancer in the era of neoadjuvant therapyClayton T Marcinak, William F Parker, Alexander A Parikh, et al.
Annals of Surgical Oncology|June 15, 2026
ASO Visual Abstract: Benefit of Adjuvant Therapy after Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysisMichael C Frey, Victor Lopez-Lopez, Alessia Benz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 13, 2015
Omission of adjuvant therapy after gastric cancer resection: development of a validated risk modelJashodeep Datta, Matthew T McMillan, Eric K Shang, et al.
Annals of Surgical Oncology|June 3, 2026
Benefit of Adjuvant Therapy After Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysisMichael C Frey, Victor Lopez-Lopez, Alessia Benz, et al.
JCI Insight|June 22, 2026
IL1RAP-expressing myeloid-stromal networks represent a therapeutic vulnerability to improve chemoimmunotherapy sensitivity in pancreatic cancerErin M Dickey, Harper M Marsh, Camilla Rydberg-Millrud, et al.
Annals of Surgery|November 20, 2020
Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery ChemotherapyJashodeep Datta, Raja R Narayan, Debra A Goldman, et al.
Pageof 14

Showing results (91-100 of 140) with videos related to

Sort By:
Pageof 14
Elife|September 15, 2022
Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical studyIago de Castro Silva, Anna Bianchi, Nilesh U Deshpande, et al.
Molecular Cancer Therapeutics|September 14, 2021
Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic CancerAustin R Dosch, Samara Singh, Xizi Dai, et al.
Journal of Surgical Oncology|October 30, 2020
Surgical management of hepatocellular carcinoma patients with portal vein thrombosis: The United States Safety Net and Academic Center Collaborative AnalysisEmily L Ryon, Joshua P Kronenfeld, Rachel M Lee, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|June 18, 2022
Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United StatesTejeshwar Jain, Prateek Sharma, Bhuwan Giri, et al.
Journal of Surgical Oncology|April 19, 2023
Accuracy of models to prognosticate survival after surgery for pancreatic cancer in the era of neoadjuvant therapyClayton T Marcinak, William F Parker, Alexander A Parikh, et al.
Annals of Surgical Oncology|June 15, 2026
ASO Visual Abstract: Benefit of Adjuvant Therapy after Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysisMichael C Frey, Victor Lopez-Lopez, Alessia Benz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 13, 2015
Omission of adjuvant therapy after gastric cancer resection: development of a validated risk modelJashodeep Datta, Matthew T McMillan, Eric K Shang, et al.
Annals of Surgical Oncology|June 3, 2026
Benefit of Adjuvant Therapy After Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysisMichael C Frey, Victor Lopez-Lopez, Alessia Benz, et al.
JCI Insight|June 22, 2026
IL1RAP-expressing myeloid-stromal networks represent a therapeutic vulnerability to improve chemoimmunotherapy sensitivity in pancreatic cancerErin M Dickey, Harper M Marsh, Camilla Rydberg-Millrud, et al.
Annals of Surgery|November 20, 2020
Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery ChemotherapyJashodeep Datta, Raja R Narayan, Debra A Goldman, et al.
Pageof 14